peritoneal carcinoma
Recently Published Documents


TOTAL DOCUMENTS

398
(FIVE YEARS 119)

H-INDEX

34
(FIVE YEARS 3)

2022 ◽  
Vol 29 (1) ◽  
pp. 231-242
Author(s):  
Hal Hirte ◽  
Raymond Poon ◽  
Xiaomei Yao ◽  
Taymaa May ◽  
Josee-Lyne Ethier ◽  
...  

Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systematic reviews and phase III trials. Articles focusing on consolidation and maintenance therapies were excluded. Results: For women with potentially resectable disease, primary cytoreductive surgery, followed by six to eight cycles of intravenous three-weekly paclitaxel and carboplatin is recommended. For those with a high-risk profile for primary cytoreductive surgery, neoadjuvant chemotherapy can be an option. Adjuvant chemotherapy with six cycles of dose-dense weekly paclitaxel plus three-weekly carboplatin can be considered for women of Japanese descent. In women with stage III or IV disease, the incorporation of bevacizumab concurrent with paclitaxel and carboplatin is not recommended for use as adjuvant therapy unless bevacizumab is continued as maintenance therapy. Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel can be considered for stage III optimally debulked women who did not receive neoadjuvant chemotherapy. However, intraperitoneal administration of chemotherapy with bevacizumab should not be considered as an option for stage II–IV optimally debulked women. Discussion: The recommendations represent a current standard of care that is feasible to implement and valued by both clinicians and patients.


2021 ◽  
Vol 116 (1) ◽  
pp. S1504-S1504
Author(s):  
Mohammad Abudalou ◽  
Marcel R. Robles ◽  
Christopher G. Stallwood

2021 ◽  
Vol 12 (2) ◽  
pp. 278-282
Author(s):  
Francesca Arezzo ◽  
Gerardo Cazzato ◽  
Vera Loizzi ◽  
Giuseppe Ingravallo ◽  
Leonardo Resta ◽  
...  

Peritoneal tuberculosis (TBP) is a very rare condition, accounting for about 1–2% of all tuberculosis cases. The diagnosis of TBP can be easily mistaken for advanced ovarian cancer (AOC) or peritoneal carcinoma because of overlapping laboratory and clinical findings. We reported the ultrasound characteristics of a case of TBP in a 67-year-old woman who presented to our institute with a 1-month history of intermittent lower abdominal pain, fever, and asthenia. Overall, 20 biopsy-retrieved specimen histopathological features were suggestive of peritoneal tuberculosis. Gynecologic ultrasound revealed increased adnexa with multiple nodular formations spread across the surface, suggestive of caseous nodules. Although this is a rare occurrence, clinicians should consider TBP as a differential diagnosis of ovarian or peritoneal cancer.


Sign in / Sign up

Export Citation Format

Share Document